SVB Leerink Upgrades Spruce Biosciences to Outperform, Raises Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
SVB Leerink analyst Joseph Schwartz has upgraded Spruce Biosciences (NASDAQ:SPRB) from Market Perform to Outperform and raised the price target from $3 to $9.
September 08, 2023 | 11:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Spruce Biosciences has been upgraded to Outperform by SVB Leerink, with a raised price target from $3 to $9.
The upgrade from Market Perform to Outperform by SVB Leerink indicates a positive outlook for Spruce Biosciences. The significant increase in the price target from $3 to $9 suggests that the analyst sees substantial upside potential for the stock. This could lead to increased investor interest and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100